Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response

Critical Reviews in Immunology

Volumn 31, Issue 5, 2011, Pages 357-377

  Noman, Muhammad Zaeem ^a,b   Messai, Yosra ^a,b   Carré, Thibault ^a,b   Akalay, Intissar ^a,b   Méron, Marine ^a,b   Janji, Bassam ^c   Hasmim, Meriem ^a,b   Chouaib, Salem ^a,b  

^a Unite Inst Natl de la S et de la Rech Med U753 Immunol des Tumeurs Humaines   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Antitumor response and tumor progression; HIF 1 ; Hypoxia

Indexed keywords

GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; MICRORNA;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER IMMUNOTHERAPY; CELL INTERACTION; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; REVIEW; SRC HOMOLOGY DOMAIN; STROMA; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 82755186508     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v31.i5.10     Document Type: Review

References (134)

1. Semenza GL. Hif-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des. 2009;15(33):3839-3843.
2. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002 Jan;2(1):38-47.
3. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med. 2007 Dec;85(12):1301-1307.
4. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008 Jun;8(6):425-437.
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loophelix-Pas heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-5514.
6. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (Hif-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997 Sep 5;272(36):22642-22647.
7. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the Hif transactivation domain a hypoxic switch. Science. 2002 Feb 1;295(5556):858-861.
8. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010 Feb 4;29(5):625-34.
9. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ. 2008 Apr;15(4):628-634.
10. Lau KW, Tian YM, Raval RR, Ratcliffe PJ, Pugh CW. Target Gene Selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer. 2007 Apr 23;96(8):1284-1292.
11. Makino Y, Uenishi R, Okamoto K, Isoe T, Hosono O, Tanaka H, Kanopka A, Poellinger L, Haneda M, Morimoto C. transcriptional up-regulation of inhibitory Pas domain protein gene expression by hypoxia-inducible factor 1 (Hif-1): a negative feedback regulatory circuit in Hif-1-mediated signaling in hypoxic cells. J Biol Chem. 2007 May 11;282(19):14073-14082.
12. Semenza GL. Targeting Hif-1 for cancer therapy. Nat Rev Cancer. 2003 Oct;3(10):721-732.
13. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007 May 4;129(3):465-72.
14. Lukashev D, Ohta A, Sitkovsky M. Hypoxiadependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev. 2007 Jun;26(2):273-279.
15. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. Hif-2alpha promotes hypoxic cell proliferation by enhancing C-Myc transcriptional activity. Cancer Cell. 2007 Apr;11(4):335-347.
16. Gordan JD, Thompson CB, Simon MC. Hif and C-Myc: Sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007 Aug;12(2):108-113.
17. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM, Cowburn AS, Johnson N, Chilvers ER. Hypoxia-induced neutrophil survival is mediated by Hif-1alpha-dependent Nf-Kappab activity. J Exp Med. 2005 Jan 3;201(1):105-15.
18. Sica A, Melillo G, Varesio L. Hypoxia: a doubleedged sword of immunity. J Mol Med. 2011 Jul;89(7):657-665.
19. Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of inflammation. Curr Top Microbiol Immunol. 2010;345:105-120.
20. Rinaldo JE, Basford RE. Neutrophil-endothelial interactions: modulation of neutrophil activation responses by endothelial cells. Tissue Cell. 1987;19(5):599-606.
21. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000 Oct;192(2):150-158.
22. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010 Oct 1;70(19):7465-7475.
23. Almholt K, Johnsen M. Stromal Cell involvement in cancer. recent results. Cancer Res. 2003;162:31-42.
24. Mantovani A, Allavena P, Sica A. Tumourassociated macrophages as a prototypic type ii polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004 Jul;40(11):1660-1667.
25. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Hif-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010 Oct 25;207(11):2439-53.
26. Mancino A, Schioppa T, Larghi P, Pasqualini F, Nebuloni M, Chen IH, Sozzani S, Austyn JM, Mantovani A, Sica A. Divergent effects of hypoxia on dendritic cell functions. Blood. 2008 Nov 1;112(9):3723-3734.
27. Rama I, Bruene B, Torras J, Koehl R, Cruzado JM, Bestard O, Franquesa M, Lloberas N, Weigert A, Herrero-Fresneda I, Gulias O, Grinyo JM. Hypoxia stimulus: an adaptive immune response during dendritic cell maturation. Kidney Int. 2008 Apr;73(7):816-825.
28. Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, Gerlach RG, Volke M, Glasner J, Warnecke C, Wiesener MS, Eckardt KU, Steinkasserer A, Hensel M, Willam C. Hypoxia and Hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol. 2008 Apr 1;180(7):4697-4705.
29. Sun J, Zhang Y, Yang M, Xie Q, Li Z, Dong Z, Yang Y, Deng B, Feng A, Hu W, Mao H, Qu X. Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7 expression: the role of adenosine receptor a(2). Cell Mol Immunol. 2010 Jan;7(1):77-82.
30. Carraro F, Pucci A, Pellegrini M, Pelicci PG, Baldari CT, Naldini A. P66shc is involved in promoting hif-1alpha accumulation and cell death in hypoxic T cells. J Cell Physiol. 2007 May;211(2):439-47.
31. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y, Poellinger L, Okada Y, Morimoto C, Tanaka H. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol. 2003 Dec 15;171(12):6534-6540.
32. Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH. Vhlh Gene deletioninduces Hif-1-mediated cell death in thymocytes. Mol Cell Biol. 2004 Oct;24(20):9038-47.
33. Van Belle H, Goossens F, Wynants J. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol. 1987 May;252(5 Pt 2):H886-H893.
34. Winn HR, Rubio GR, Berne RM. The role of adenosine in the regulation of cerebral blood flow. J Cereb Blood Flow Metab. 1981;1(3):239-244.
35. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res. 2008 Oct 1;14(19):5947-5952.
36. Lukashev D, Klebanov B, Kojima H, Grinberg A, Ohta A, Berenfeld L, Wenger RH, Sitkovsky M. Cutting Edge: Hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of Cd4+ and Cd8+ T lymphocytes. J Immunol. 2006 Oct 15;177(8):4962-5.
37. Thiel M, Caldwell CC, Kreth S, Kuboki S, Chen P, Smith P, Ohta A, Lentsch AB, Lukashev D, Sitkovsky MV. Targeted deletion of Hif-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One. 2007;2(9):e853.
38. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H. Hif1{alpha}-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of Th17 and Treg cells. J Exp Med. 2011 Jul 4;208(7):1367-1376.
39. Kojima H, Gu H, Nomura S, Caldwell CC, Kobata T, Carmeliet P, Semenza GL, Sitkovsky MV. Abnormal B Lymphocyte Development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2170-2174.
40. Kojima H, Kobayashi A, Sakurai D, Kanno Y, Hase H, Takahashi R, Totsuka Y, Semenza GL, Sitkovsky MV, Kobata T. Differentiation stage-specific requirement in hypoxia-inducible factor-1alpha-regulated glycolytic pathway during murine B cell development in bone marrow. J Immunol. 2010 Jan 1;184(1):154-163.
41. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007 Jun;26(2):319-331.
42. Volm M, Koomagi R. Hypoxia-inducible factor (Hif-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000 May-Jun;20(3A):1527-1533.
43. Liu XH, Yu EZ, Li YY, Kagan E. Hif-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J Cell Biochem. 2006 Mar 1;97(4):755-765.
44. Fink T, Ebbesen P, Koppelhus U, Zachar V. Natural Killer cell-mediated basal and interferonenhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions. Scand J Immunol. 2003 Dec;58(6):607-612.
45. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, Graham CH. Hypoxia increases tumor cell shedding of Mhc class I chain-related molecule: role of nitric oxide. Cancer Res. 2008 Jun 15;68(12):4746-4753.
46. Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F, Giuliani M, Pichon C, Azzarone B, Mazure N, Romero P, Mami-Chouaib F, Chouaib S. The cooperative induction of hypoxia-inducible factor-1 alpha and stat3 during hypoxia induced an impairment of tumor susceptibility to Ctl-mediated cell lysis. J Immunol. 2009 Mar 15;182(6):3510-3521.
47. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell. 1999 Aug 6;98(3):295-303.
48. Catlett-Falcone R, Dalton WS, Jove R. Stat proteins as novel targets for cancer therapy. signal transducer an activator of transcription. Curr Opin Oncol. 1999 Nov;11(6):490-6.
49. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med. 2004 Jan;10(1):48-54.
50. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15;67(20):9630-9636.
51. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009 Mar 15;69(6):2506-2513.
52. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009 Mar 15;69(6):2514-2522.
53. Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest. 2003 Mar;111(5):595-597.
54. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010 Apr;22(2):124-131.
55. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010 Oct 22;40(2):280-293.
56. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxiainduced autophagy is mediated through hypoxiainducible factor induction of Bnip3 and Bnip3l via their Bh3 domains. Mol Cell Biol. 2009 May;29(10):2570-2581.
57. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol. 2010 Apr;22(2):177-180.
58. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky M, Wouters BG. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes Map1lc3b and Atg5. J Clin Invest. 2010 Jan 4;120(1):127-141.
59. Livesey KM, Tang D, Zeh HJ, Lotze MT. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs. 2009 Dec;10(12):1269-1279.
60. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature. 2011 Jan 20;469(7330):323-335.
61. Chemali M, Radtke K, Desjardins M, English L. Alternative pathways for Mhc class I presentation: a new function for autophagy. Cell Mol Life Sci. 2011 May;68(9):1533-1541.
62. Crotzer VL, Blum JS. Autophagy and adaptive immunity. Immunology. 2010 Sep;131(1):9-17.
63. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene Lin-14 by Lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993 Dec 3;75(5):855-862.
64. Alvarez-Garcia I, Miska EA. Microrna functions in animal development and human disease. Development. 2005 Nov;132(21):4653-4662.
65. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M. A microrna component of the hypoxic response. Cell Death Differ. 2008 Apr;15(4):667-671.
66. Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, Ivan M. Regulation of microrna expression: the hypoxic component. Cell Cycle. 2007 Jun 15;6(12):1426-1431.
67. Loscalzo J. The cellular response to hypoxia: tuning the system with micrornas. J Clin Invest. 2010 Nov 1;120(11):3815-3817.
68. Devlin C, Greco S, Martelli F, Ivan M. Mir-210: More than a silent player in hypoxia. IUBMB Life. 2011 Feb;63(2):94-100.
69. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible Mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009 Sep 24;35(6):856-867.
70. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL. Hsa-Mir-210 Is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010 May 1;116(9):2148-2158.
71. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. Hsa-Mir-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008 Mar 1;14(5):1340-1348.
72. Huang X, Le QT, Giaccia AJ. Mir-210- micromanager of the hypoxia pathway. Trends Mol Med. 2010 May;16(5):230-237.
73. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S. Hypoxia induces microrna Mir-210 in vitro and in vivo Ephrin-A3 and neuronal pentraxin 1 are potentially regulated by Mir-210. FEBS Lett. 2008 Jul 9;582(16):2397-2401.
74. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via Mir-210 expression by targeting caspase-8-associated protein 2. J Biol Chem. 2009 Nov 27;284(48):33161-33168.
75. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002 Jun;2(6):442-454.
76. Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka BM. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science. 2004 Dec 24;306(5705):2261-2264.
77. Meulemans D, Bronner-Fraser M. Generegulatory interactions in neural crest evolution and development. Dev Cell. 2004 Sep;7(3): 291-299.
78. Barrallo-Gimeno A, Nieto MA. The snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005 Jul;132(14):3151-3161.
79. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-142.
80. Jiang J, Tang YL, Liang XH. Emt: A new vision of hypoxia promoting cancer progression. Cancer Biol Ther. 2011 Apr 15;11(8):714-723.
81. Sleeman JP, Thiery JP. Snapshot: the epithelial- mesenchymal transition. cell. 2011 Apr 1;145(1):162 e1.
82. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. Tgf{Beta}/Tnf{Alpha}-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a Claudin-low phenotype. Cancer Res. 2011 Jul 1;71(13):4707-4719.
83. Zavadil J, Bottinger EP. Tgf-beta and epithelialto-mesenchymal transitions. Oncogene. 2005 Aug 29;24(37):5764-5774.
84. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev. 2007 Jan;3(1):18-29.
85. Nishi H, Nakada T, Hokamura M, Osakabe Y, Itokazu O, Huang LE, Isaka K. Hypoxia-inducible factor-1 transactivates transforming growth factor-beta3 in trophoblast. Endocrinology. 2004 Sep;145(9):4113-4118.
86. Schaffer L, Scheid A, Spielmann P, Breymann C, Zimmermann R, Meuli M, Gassmann M, Marti HH, Wenger RH. Oxygen-regulated expression of Tgf-Beta 3, a growth factor involved in trophoblast differentiation. Placenta. 2003 Nov;24(10):941-950.
87. Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxiainducible factor and transforming growth factorbeta- dependent mechanisms. Liver Int. 2010 May;30(5):669-682.
88. Lee JD, Hempel N, Lee NY, Blobe GC. The type III Tgf-beta receptor suppresses breast cancer progression through Gipc-mediated inhibition of Tgf-beta signaling. Carcinogenesis. 2010 Feb;31(2):175-183.
89. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, Wirth T. Nf-Kappab promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 2010 Sep 28;295(2):214-228.
90. Taylor CT, Cummins EP. The role of Nf-Kappab in hypoxia-induced gene expression. Ann N Y Acad Sci. 2009 Oct;1177:178-184.
91. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT. Prolyl hydroxylase-1 negatively regulates Ikappab kinase-beta, giving insight into hypoxia-induced Nfkappab activity. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18154-18159.
92. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of Tgf-Beta/Smad and Jagged1/notch signalling in epithelial-to-mesenchymal transition. Embo J. 2004 Mar 10;23(5):1155-1165.
93. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005 Nov;9(5):617-628.
94. Chen J, Imanaka N, Chen J, Griffin JD. Hypoxia potentiates notch signaling in breast cancer leading to decreased E-Cadherin expression and increased cell migration and invasion. Br J Cancer. 2010 Jan 19;102(2):351-360.
95. Sun S, Ning X, Zhang Y, Lu Y, Nie Y, Han S, Liu L, Du R, Xia L, He L, Fan D. Hypoxiainducible factor-1alpha induces twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int. 2009 Jun;75(12):1278-1287.
96. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of twist by Hif-1alpha promotes metastasis. Nat Cell Biol. 2008 Mar;10(3):295-305.
97. Liang X, Zheng M, Jiang J, Zhu G, Yang J, Tang Y. Hypoxia-inducible factor-1 alpha, in association with Twist2 and Snip1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol. 2010 Feb;47(2):92-97.
98. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA. The transcriptional repressor snail promotes mammary tumor recurrence. Cancer Cell. 2005 Sep;8(3):197-209.
99. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, Konishi I. Hypoxia attenuates the expression of E-Cadherin via up-regulation of snail in ovarian carcinoma cells. Am J Pathol. 2003 Oct;163(4):1437-1447.
100. Lundgren K, Nordenskjold B, Landberg G. Hypoxia, snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer. 2009 Nov 17;101(10):1769-1781.
101. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006 Apr 27;440(7088): 1222-1226.
102. Gupta R, Chetty C, Bhoopathi P, Lakka S, Mohanam S, Rao JS, Dinh DE. Downregulation of Upa/Upar inhibits intermittent hypoxiainduced epithelial-mesenchymal transition (Emt) in Daoy and D283 medulloblastoma cells. Int J Oncol. 2011 Mar;38(3):733-744.
103. Luo D, Wang J, Li J, Post M. Mouse snail is a target gene for Hif. Mol Cancer Res. 2011 Feb;9(2):234-245.
104. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 Nov 1;414(6859):105-111.
105. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003 Dec;3(12):895-902.
106. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008 Oct;8(10):755-768.
107. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-7026.
108. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ. Physiologic oxygen concentration enhances the stem-like properties of Cd133+ human glioblastoma cells in vitro. Mol Cancer Res. 2009 Apr;7(4):489-497.
109. Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, Bocchetta M. Oxygen concentration determines the biological effects of notch-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007 Sep 1;67(17):7954-7959.
110. Morrison SJ, Perez SE, Qiao Z, Verdi JM, Hicks C, Weinmaster G, Anderson DJ. Transient notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell. 2000 May 26;101(5):499-510.
111. Wilson A, Radtke F. Multiple functions of notch signaling in self-renewing organs and cancer. FEBS Lett. 2006 May 22;580(12):2860-2868.
112. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009 Jun 2;15(6):501-513.
113. Pietras A, Gisselsson D, Ora I, Noguera R, Beckman S, Navarro S, Pahlman S. High levels of Hif-2alpha highlight an immature neural crestlike neuroblastoma cell cohort located in a perivascular niche. J Pathol. 2008 Mar;214(4):482-488.
114. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009 Oct 15;8(20): 3274-3284.
115. Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting Hif1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011 Apr 8;8(4):399-411.
116. Bar EE. Glioblastoma, cancer stem cells and hypoxia. Brain Pathol. 2011 Mar;21(2):119-129.
117. Quintero M, Brennan PA, Thomas GJ, Moncada S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. Cancer Res. 2006 Jan 15;66(2):770-774.
118. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. Vhl and Hif signalling in renal cell carcinogenesis. J Pathol. 2010 Jun;221(2):125-138.
119. Li M, Kim WY. Two sides to every story: the HIFdependent and HIF-independent functions of pVHL. J Cell Mol Med. 2011;15:187-195.
120. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of Hif2alpha is sufficient to suppress Pvhl-defective tumor growth. PLoS Biol. 2003 Dec;1(3):e83.
121. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of Glut1 Mrna by hypoxia-inducible factor-1. Interaction between H-Ras and hypoxia. J Biol Chem. 2001 Mar 23;276(12):9519-9525.
122. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem. 2002 Oct 18;277(42):40112-40117.
123. Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC. Oncogenic Kras and Braf differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res. 2009 Nov 1;69(21):8499-8506.
124. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Mutant V600e Braf increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res. 2007 Apr 1;67(7):3177-3184.
125. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic Braf regulates melanoma proliferation through the lineage specific factor Mitf. PLoS One. 2008;3(7):e2734.
126. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribere L, Bertolotto C, Virolle T, Barbry P, Pouyssegur J, Ponzio G, Ballotti R. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (Mitf) in melanoma cells. J Cell Biol. 2005 Jul 4;170(1):49-59.
127. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. Hif overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of Hif stability. Cancer Cell. 2005 Aug;8(2):143-153.
128. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links Tca cycle dysfunction to oncogenesis by inhibiting Hif-alpha prolyl hydroxylase. Cancer Cell. 2005 Jan;7(1):77-85.
129. Hay N. The Akt-Mtor tango and its relevance to cancer. Cancer Cell. 2005 Sep;8(3):179-183.
130. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Loss of Pten facilitates Hif-1-mediated gene expression. Genes Dev. 2000 Feb 15;14(4):391-396.
131. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 Kinase/Akt in Her2 overexpressing cells. Cancer Res. 2005 Apr 15;65(8):3257-3263.
132. Lee HY, Lee T, Lee N, Yang EG, Lee C, Lee J, Moon EY, Ha J, Park H. Src activates Hif-1alpha not through direct phosphorylation of Hif-1alpha specific prolyl-4 hydroxylase 2 but through activation of the Nadph oxidase/Rac pathway. Carcinogenesis. 2011 May;32(5):703-712.
133. Chouaib S, El Hage F, Benlalam H, Mami-Chouaib F. [immunotherapy of cancer: promise and reality]. Med Sci (Paris). 2006 Aug-Sep;22(8-9):755-759.
134. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360